Semaglutide dose and dosage, as documented — not as advice

Read this first

This page logs the Semaglutide dose and dosage figures that appear in the approved label and in published trials. It is a record of what was studied and what the label documents — not a recommendation, and not instructions for anyone. Nothing here tells a reader what to take.

The pattern across uses is the same: start low, raise the dose slowly. Doctors and trials begin at a small dose and step it up every few weeks. The slow ramp exists mainly to limit nausea, which clusters around each increase ^[16]. The injection is taken once a week; the tablet is taken once a day on an empty stomach. The drug stays in the body a long time — a half-life of about a week ^[12]. What follows is documented dosing, by route.

Semaglutide dose — the documented titration

Semaglutide dose

The semaglutide dose is escalated in steps. For chronic weight management, the documented subcutaneous schedule escalates stepwise: 0.25 mg once weekly for weeks 1-4, then 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16), and a 2.4 mg once-weekly maintenance dose. The 2.4 mg dose is the one studied in STEP 1, where it produced a mean -14.9% body-weight change at 68 weeks ^[1].

For type 2 diabetes, the documented subcutaneous schedule starts at 0.25 mg once weekly (an initiation, non-therapeutic dose), then 0.5 mg, then 1.0 mg maintenance, with a 2.0 mg dose studied in the SUSTAIN FORTE program. These are label- and protocol-documented figures, recorded here in the third person.

Semaglutide dosage by injection vs the oral route

Semaglutide dosage

Semaglutide dosage splits by route.

Semaglutide injection

The semaglutide injection is subcutaneous and once weekly — the route used in STEP, SUSTAIN-6, SELECT, and FLOW ^[1][2][3][6]. The week-long half-life is what allows once-weekly dosing ^[12].

Oral semaglutide

Oral semaglutide is a once-daily tablet co-formulated with an absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently raises local stomach pH so the peptide can be absorbed ^[21]. Its documented type 2 diabetes schedule is 3 mg daily for 30 days, then 7 mg, then 14 mg — taken on an empty stomach, about 30 minutes before the first food, drink, or other oral medication, with no more than ~120 mL of water ^[21]. Higher oral doses (25 mg and 50 mg once daily) were studied in obesity research programs.

Half-life and how long it stays in the system

Semaglutide's elimination half-life is approximately one week (commonly cited as ~165-168 hours) for both the subcutaneous and oral forms, with effectively complete clearance roughly five weeks after the final dose ^[12]. Two structural features drive this: strong, reversible albumin binding via the C18 fatty di-acid side chain, and DPP-4 resistance from the position-8 substitution ^[12]. The long tail is also why label guidance advises stopping well before a planned pregnancy ^[11].

Oral semaglutide bioavailability and why fasted dosing matters

Oral semaglutide's bioavailability is low — roughly 0.4-1% even with SNAC ^[12][21]. That is the documented reason the tablet must be taken fasted with minimal water: food, drink, or other medication in the stomach can substantially reduce how much is absorbed, and therefore the effect ^[21]. This is a formulation requirement, not a toxicity. A separate review found that the drug's slowed gastric emptying generally does not cause clinically significant interactions, while advising monitoring for narrow-therapeutic-index oral drugs during titration ^[22].

Compounded semaglutide

Compounded semaglutide is semaglutide prepared by a compounding pharmacy rather than the approved manufactured product. During a federally declared shortage (roughly 2022 to early 2025), compounding pharmacies were permitted to produce it; that pathway was curtailed once the shortage was declared resolved in early 2025 ^[11].

Compounded preparations fall outside the approved-product evidence base. The documented concerns during the shortage included dosing errors, adverse events requiring hospitalization, and products with unverified or non-pharmaceutical active ingredients ^[5]. This site logs that as a regulatory and safety distinction; it does not evaluate, endorse, or source any product.